Cover Image
市場調查報告書

低血糖症 : 開發平台分析

Hypoglycemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229785
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
低血糖症 : 開發平台分析 Hypoglycemia - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 77 Pages
簡介

低血糖症發生於血液中的葡萄糖過低時。葡萄糖是人體重要的能源來源。低血糖症雖然發病相當突然,但可輕易藉由消費高血糖值血液來迅速控制。低血糖的症狀有空腹感和顫抖、神經質、冷汗、暈眩/朦朧狀態、睡意、混亂、睡眠障礙、不安感、四肢無力感等。睡眠中的低血糖徵兆,則指怪聲和惡夢,發汗造成睡衣和床單潮濕,起床時易感到疲勞和焦躁及困惑等。同時更會出現各種血糖症治療藥的副作用。飲食不規則進食不足,身體活動增加,攝取酒精飲料等理由也會造成低血糖症,或注射或服用促使胰島素增加之藥物的人們身上也一樣會發生。

本報告提供全球各國治療低血糖症用的開發中產品開發情形相關分析、彙整開發中產品的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)進展狀況)、最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

低血糖症概要

治療藥的開發

  • 低血糖症開發中產品:概要
  • 低血糖症開發中產品:比較分析

各企業開發中的低血糖症治療藥

大學/研究機關研究中的低血糖症治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

低血糖症治療藥:開發中的產品一覽(各企業)

低血糖症治療藥:研究中的產品一覽(大學/研究機關)

低血糖症開發治療藥的企業

  • Biodel Inc.
  • Eli Lilly and Company
  • Heptares Therapeutics Limited
  • Novartis AG
  • SkyePharma Plc
  • USV Limited
  • XERIS Pharmaceuticals, Inc.
  • XOMA Corporation
  • Zealand Pharma A/S

低血糖症:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各行動機制
  • 各投藥法
  • 各分子類型
  • 各治療分類

藥物簡介

  • 低血糖症生技藥品
  • glucagon
  • pasireotide
  • GLP-1 受體拮抗劑
  • terbutaline sulphate
  • XOMA-358
  • ZP-4207

低血糖症治療藥:最新的藥物簡介

低血糖症治療藥:開發暫停的產品

低血糖症治療藥:開發中止的產品

低血糖症相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8287IDB

Summary

Global Markets Direct's, 'Hypoglycemia - Pipeline Review, H2 2016', provides an overview of the Hypoglycemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hypoglycemia
  • The report reviews pipeline therapeutics for Hypoglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hypoglycemia therapeutics and enlists all their major and minor projects
  • The report assesses Hypoglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hypoglycemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hypoglycemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypoglycemia Overview
  • Therapeutics Development
    • Pipeline Products for Hypoglycemia - Overview
  • Hypoglycemia - Therapeutics under Development by Companies
  • Hypoglycemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hypoglycemia - Products under Development by Companies
  • Hypoglycemia - Companies Involved in Therapeutics Development
    • Biodel Inc.
    • Eiger BioPharmaceuticals, Inc.
    • Eli Lilly and Company
    • Heptares Therapeutics Limited
    • Novartis AG
    • Sanofi
    • SkyePharma Plc
    • Therakind Limited
    • USV Limited
    • XERIS Pharmaceuticals, Inc.
    • XOMA Corporation
    • Zealand Pharma A/S
    • Zosano Pharma Corporation
  • Hypoglycemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Drug for Hypoglycemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • exendin-(9-39) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glucagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glucagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glucagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glucagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3143753 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3185643 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-900018 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide for Hypoglycemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-438544 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • terbutaline sulphate MR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XOMA-129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XOMA-358 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZP-4207 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hypoglycemia - Dormant Projects
  • Hypoglycemia - Discontinued Products
  • Hypoglycemia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 13, 2016: Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia
      • May 10, 2016: Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery
      • Apr 27, 2016: XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
      • Apr 04, 2016: XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
      • Feb 04, 2016: Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes
      • Oct 26, 2015: XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism
      • Oct 13, 2015: Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia
      • Sep 09, 2015: Results from a multiple-dose Phase Ib trial support the potential of Zealand's stable glucagon analogue, ZP4207, for the correction of mild to moderate hypoglycemia
      • Jun 26, 2015: Phase I trial results for Zealand's glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy
      • Jun 23, 2015: Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia
      • May 20, 2015: Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207
      • Mar 16, 2015: Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial
      • Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting
      • Mar 05, 2015: XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015
      • Dec 04, 2014: Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hypoglycemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Hypoglycemia - Pipeline by Biodel Inc., H2 2016
  • Hypoglycemia - Pipeline by Eiger BioPharmaceuticals, Inc., H2 2016
  • Hypoglycemia - Pipeline by Eli Lilly and Company, H2 2016
  • Hypoglycemia - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Hypoglycemia - Pipeline by Novartis AG, H2 2016
  • Hypoglycemia - Pipeline by Sanofi, H2 2016
  • Hypoglycemia - Pipeline by SkyePharma Plc, H2 2016
  • Hypoglycemia - Pipeline by Therakind Limited, H2 2016
  • Hypoglycemia - Pipeline by USV Limited, H2 2016
  • Hypoglycemia - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016
  • Hypoglycemia - Pipeline by XOMA Corporation, H2 2016
  • Hypoglycemia - Pipeline by Zealand Pharma A/S, H2 2016
  • Hypoglycemia - Pipeline by Zosano Pharma Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hypoglycemia - Dormant Projects, H2 2016
  • Hypoglycemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hypoglycemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top